Literature DB >> 15653379

Brain natriuretic peptide predicts serious cardiac allograft rejection independent of hemodynamic measurements.

Audrey H Wu1, Monica L Johnson, Keith D Aaronson, David Gordon, David B S Dyke, Todd M Koelling.   

Abstract

BACKGROUND: Serum brain natriuretic peptide (BNP) has been reported to be elevated in heart transplant recipients with both cellular and vascular rejection. Whether BNP can be used to help predict the severity of rejection is not well established.
METHODS: We analyzed serial BNP measurements obtained during endomyocardial biopsy procedures in consecutive heart transplant patients occurring >45 days after transplantation. To eliminate potential confounding from prior rejection episodes, we included only observations in which the previous biopsy grade was 0 or 1A. Multivariable linear regression was performed examining the outcome of increasing seriousness of rejection, defined as grade 0 < 1A < 2 < 1B < 3A < vascular rejection. A univariable logistic regression model was performed using log-transformed BNP as a predictor of vascular rejection.
RESULTS: There were 77 patients, with 161 separate observations. Median time between transplantation and first assessment was 6.0 months (interquartile range, 2.1, 31.6). Using multivariable linear regression, 3 factors were significantly associated with biopsy score: pulmonary capillary wedge pressure (p < 0.0001), BNP (p = 0.003), and heart rate (p = 0.01). Even after other significant univariable predictors (including pulmonary capillary wedge pressure) were forced into the model, BNP remained a significant predictor of biopsy score (p = 0.02). Log BNP was a significant univariable predictor of vascular rejection, with an odds ratio of 12.55 (per 1 unit increase, 95% confidence interval 3.43-45.84; p = 0.0001) and a model c-statistic of 0.91.
CONCLUSIONS: BNP predicts new episodes of serious cardiac allograft rejection, particularly vascular rejection, independent of hemodynamic measurements, and may be a useful part of rejection surveillance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653379     DOI: 10.1016/j.healun.2003.10.012

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

Review 1.  Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation.

Authors:  Peter J Kennel; P Christian Schulze
Journal:  Curr Heart Fail Rep       Date:  2015-10

Review 2.  [Biomarker for diagnosis of rejection after heart transplantation].

Authors:  Matthias Frick; Herwig Antretter; Otmar Pachinger; Gerhard Pölzl
Journal:  Herz       Date:  2010-01       Impact factor: 1.443

3.  Cardiac Allograft Rejection Induces Changes in Nucleocytoplasmic Transport: RANGAP1 as a Potential Non-Invasive Biomarker.

Authors:  Silvia Lozano-Edo; Esther Roselló-Lletí; Ignacio Sánchez-Lázaro; Estefanía Tarazón; Manuel Portolés; Maryem Ezzitouny; Raquel Lopez-Vilella; Miguel Angel Arnau; Luis Almenar; Luis Martínez-Dolz
Journal:  J Pers Med       Date:  2022-05-31

Review 4.  Where, when and how much: regulation of myelin proteolipid protein gene expression.

Authors:  P A Wight; A Dobretsova
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

5.  B-type natriuretic peptide is upregulated by c-Jun N-terminal kinase and contributes to septic hypotension.

Authors:  Matthew Hoffman; Ioannis D Kyriazis; Alexandra Dimitriou; Santosh K Mishra; Walter J Koch; Konstantinos Drosatos
Journal:  JCI Insight       Date:  2020-04-23

6.  Brain natriuretic Peptide production and secretion in inflammation.

Authors:  Tsuneo Ogawa; Adolfo J de Bold
Journal:  J Transplant       Date:  2012-11-28

7.  Assessment of sub-clinical acute cellular rejection after heart transplantation: comparison of cardiac magnetic resonance imaging and endomyocardial biopsy.

Authors:  Christian Krieghoff; Markus J Barten; Lysann Hildebrand; Matthias Grothoff; Lukas Lehmkuhl; Christian Lücke; Claudia Andres; Stefan Nitzsche; Franziska Riese; Martin Strüber; Friedrich Wilhelm Mohr; Matthias Gutberlet
Journal:  Eur Radiol       Date:  2014-06-04       Impact factor: 5.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.